Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the metabolic pathway of 5-fluorouracil (5-FU) and other fluoropyrimidines to inactive compounds. For this reason, severe, life-threatening toxicities may occur in patients with deficient DPD activity when a...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Michelucci, Angela, Di Leo, Angelo, Cantore, Maurizio, Bordonaro, Roberto, Simi, Paolo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556010/
https://www.ncbi.nlm.nih.gov/pubmed/26330892
http://dx.doi.org/10.1186/s13167-015-0039-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556010/
https://www.ncbi.nlm.nih.gov/pubmed/26330892
http://dx.doi.org/10.1186/s13167-015-0039-x

Ejemplares similares